Navigation Links
OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
Date:2/4/2009

>

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning the potential survival benefit of OGX-011, anticipated clinical development activities, timing of these activities, the ability of future trials to demonstrate clinical benefit and the potential for regulatory approvals. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, the possibility that any benefit in patient survival will not be maintained or will become less substantial as patient survival follow up continues, risks that clinical trials will not be successful or confirm earlier clinical trial results, including the risk that the survival benefit will not be confirmed by a Phase 3 clinical trial, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of a Phase 3 clinical trial, the timing and costs of clinical trials and regulatory approvals will be different than management currently anticipates, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal year 2007 and its most recently filed Quarterly Report on Form 10-Q. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... IRVINE, Calif. , Sept. 15, 2014 /PRNewswire/ ... a new viral transport solution for safe ambient ... prior to molecular testing. Importantly, the infectivity of agents ... solution while maintaining the integrity of the viral ... news of the recent Ebola epidemic in ...
(Date:9/15/2014)... , Sept. 15, 2014 Research and ... Exome Sequencing Market by Product, by Services, by Technology, by ... offering. Whole Exome Sequencing (WES) is next-generation ... genome, i.e. the exon. The exome, which is the total ... the total genome and is actually converted into proteins after ...
(Date:9/15/2014)... Santa Paula, CA (PRWEB) September 15, 2014 ... of long term implantable silicones for the medical ... strength, responsive silicone gel for the implantable medical ... incorporates a unique crosslink technology delivering a silicone ... adhesion. The Dual Matrix technology consists of ...
(Date:9/15/2014)... septembre 2014 La deuxième édition annuelle ... (semaine internationale sur la sensibilisation au plasma) sera ... de la Plasma Protein Therapeutics Association ... l,IPAW vise à : , Sensibiliser ... collecte du plasma-aphérèse , Reconnaître la contribution ...
Breaking Biology Technology:Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 2L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 3
... DENVER, Nov. 18, 2010 BioSpace ... Campaign this morning, showcasing biotechnological, pharmaceutical ... States and Canada. (Logo: http://photos.prnewswire.com/prnh/20040907/CLTU006LOGO) ... campaign promotes life science organizations within Oregon, ...
... Inc. (OTCBB: GNLK ), a leading consumer genomics biotech company, today ... Highlights: Gross Profit Margin ... for the second year in a row GeneLink announces Private ... GeneLink,s CEO stated, "The third quarter of 2010 continues to reflect ...
... Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are ...
Cached Biology Technology:BioSpace Highlights the Northwest's Growing Life Science Region 2GeneLink Reports Third Quarter Results 2Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 2Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 3Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 4Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 5Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 6Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 7Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 8Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 9Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 10Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 11
(Date:9/16/2014)... votes for independence later this week, its Government could ... that fracking is necessary, research has revealed. , The ... public perception of shale gas extraction in the UK ... north of the border are the least supportive of ... in the University,s School of Geography, said: "The clear ...
(Date:9/16/2014)... waters of Southeast Alaska to the white sand beaches ... and tourist towns, coastal residents around the U.S. share ... along political lines. That,s a primary finding of a ... this month in the journal Society & Natural ... differences from place to place to place. Each environment ...
(Date:9/16/2014)... million gallons of oil into Alaska,s Prince William Sound. ... in the Gulf of Mexico in 2010. According to ... Research , news coverage of environmental disasters serves to ... the way fossil fuels are used. , "We found ... events helped to resolve many of the cultural anxieties ...
Breaking Biology News(10 mins):Scottish people most sceptical on fracking, survey shows 2Scottish people most sceptical on fracking, survey shows 3Politics divide coastal residents' views of environment, UNH research finds 2Politics divide coastal residents' views of environment, UNH research finds 3Exxon Valdez 2014: Does media coverage of manmade disasters contribute to consumer complacency? 2
... a mission to sniff out trouble and display their ... of Naval Research (ONR)-hosted "Top Dog Demo 2012." ... move through the battle space," said Lisa Albuquerque, program ... ONR,s Expeditionary Warfare and Combating Terrorism department. "Marines can ...
... high speed rail lines in China will be the topic ... Liu takes the stage at the annual 91st Transportation Research ... gathering in transportation, if not all of engineering, with upwards ... an expert in high speed rail lines and other transportation ...
... EAST LANSING, Mich. -- A receptor found on blood platelets ... questioned may in fact be fruitful in drug testing, according ... team led by Dana Spence of MSU,s Department of Chemistry ... known as P2X1. By creating a new, simple method to ...
Cached Biology News:Marine's best friend shows explosive-detecting capabilities 2NJIT high speed rail expert to address DC conference next week 2NJIT high speed rail expert to address DC conference next week 3Chemists unlock potential target for drug development 2
... Black wall plates have low background ... crosstalk,• Not treated (or medium binding) ... and binds biomolecules through passive interactions,• ... immobilization of large molecules, such as ...
... microplate washer 100-240 V, is used for ... or V-bottom wells. The immunowash microplate washer ... positions to an accuracy of 0.1 mm ... washing. It can store up to 75 ...
... 1575 immunowash microplate washer, 100-240 V, is ... flat-, U-, or V-bottom wells. This washer ... positions to an accuracy of 0.1 mm ... washing. It can store up to 75 ...
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
Biology Products: